Armitraz 1,0 mg Tablet
PDF Leaflet Revision Date: 15-Mar-2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of early and advanced breast cancer in postmenopausal women.
Dosage (summary)
1 mg orally once daily for adults and elderly.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; no data available.
Key Drug Interactions
- Avoid co-administration with tamoxifen or oestrogen therapies
Contraindications
- Hypersensitivity to anastrozole
- Pre-menopausal women
- Pregnant/lactating women
- Severe renal impairment
- Moderate or severe hepatic disease
Common side effects
- Headache
- Hot flushes
- Nausea
- Rash
- Arthralgia
- Asthenia
Counselling Points
- Take daily at the same time
- Monitor for signs of osteoporosis
- Report any unusual bleeding
Serious warnings
- May reduce bone mineral density
- Caution in patients with osteoporosis
Important Disclaimer
The Armitraz 1,0 mg Tablet professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
